Factors Relating to 6 Minute Walk Performance in Heart Failure Patients

  • Mary C. Hendrican
  • Robert S. McKelvie
  • Neil McCartney
  • Gordon H. Guyatt
  • Salim Yusuf
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 167)

Summary

Reliable, responsive, and valid testing techniques are important in assessing symptoms, left ventricular function, and response to therapy in patients with congestive heart failure (CHF). Although left ventricular ejection fraction and New York Heart Association functional classification are valid mesures of left ventricular function and symptoms, respectively, they may be relatively insensitive to changes in patient performance. The 6 min walk (6MW) is a simple, inexpensive, and safe test of functional capacity. Patients, regardless of the severity of their heart failure, can perform the 6MW. The test is performed by having patients walk a 33 meter course for 6 min, and at the end of the allotted time the total distance covered is measured. Studies have demonstrated that the 6MW is a reproducible and valid assessment of functional capacity in patients with CHF. The 6MW performance has also been demonstrated to be an independent predictor of mortality and morbidity in heart failure patients. Therefore, the 6MW is useful for the clinical assessment of heart failure patients and, because of ease of administration, can be used in large clinical trials to assess the effects of therapy for these patients.

Keywords

Placebo Cardiol Digoxin Rosen Bronchitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bittner V, Weiner DH, Yusuf S, Rogers WJ, Mclntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M, Greenberg B, Woods PA, Bourassa MG. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 270:1702–1707, 1993.PubMedCrossRefGoogle Scholar
  2. 2.
    Szlachcic J, Massie BM, Kramer BL, Topic N, Tabau J. Correlates and prognostic implications of exercise capacity in chronic congestive heart failure. Am J Cardiol 55:1037–1042, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    Baker BJ, Wilen MM, Boyd CM, Dinh HA, Franciosa JA. Relation of right ventricular ejection fraction to exercise capacity in chronic left ventricular failure. Am J Cardiol 54:596–599, 1984.PubMedCrossRefGoogle Scholar
  4. 4.
    Higginbotham MB, Morris KG, Conn EH, Coleman RE, Cobb FR. Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am J Cardiol 51:52–60, 1983.PubMedCrossRefGoogle Scholar
  5. 5.
    Guyatt G. Use of the six-minute walk test as an outcome measure in clinical trials in chronic heart failure. Heart Failure 3:211–217, 1987.Google Scholar
  6. 6.
    Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, Jones NL, Pugsley SO. How should we measure function in patients with chronic heart and lung disease? J Chron Dis 38:517–524, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    McGavin CR, Gupta SP, McHardy GJR. Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J 1:822–823, 1976.PubMedCrossRefGoogle Scholar
  8. 8.
    Butland RJA, Pan J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and twelve-minute walking test in respiratory disease. Br Med J 284:1607–1608, 1982.CrossRefGoogle Scholar
  9. 9.
    Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure. CMAJ 132:919–923, 1985.Google Scholar
  10. 10.
    Guyatt GH, Pugsley S, Sullivan MJ, Thompson PJ, Berman LB, Jones NL, Fallen EL, Taylor DW. Effect of encouragement on walking test performance. Thorax 39:818–822, 1984.PubMedCrossRefGoogle Scholar
  11. 11.
    Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA. Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J 292:653–655, 1986.CrossRefGoogle Scholar
  12. 12.
    Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. CMAJ 134:889–895, 1986.PubMedGoogle Scholar
  13. 13.
    Gorkin L, Norvell NK, Rosen RC, Charles E, Shumaker SA, Mclntyre KM, Capone RJ, Kostis J, Niaura R, Woods P, Hosking J, Garces C, Handberg E, Ahern DK, Follick MJ. Assessment of quality of life as observed from the baseline data of the studies of left ventricular dysfunction (SOLVD) trial quality of life substudy. Am J Cardiol 71:1069–1073, 1993.PubMedCrossRefGoogle Scholar
  14. 14.
    Guyatt GH, Sullivan MJJ, Fallen E, Tihal H, Rideout E, Halcrow S, Nogradi S, Townsend M, Taylor W. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 61:371–375, 1988.PubMedCrossRefGoogle Scholar
  15. 15.
    Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 66:603–607, 1990.PubMedCrossRefGoogle Scholar
  16. 16.
    Baigrie RS, Myers MG, Kavanagh T, Guyatt G. Benefits of physical training in patients with heart failure. Can J Cardiol 8(Suppl B):107B, 1992.Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Mary C. Hendrican
  • Robert S. McKelvie
  • Neil McCartney
  • Gordon H. Guyatt
  • Salim Yusuf

There are no affiliations available

Personalised recommendations